Kostas Biliouris
Stock Analyst at BMO Capital
(0.97)
# 3,792
Out of 4,959 analysts
59
Total ratings
32.61%
Success rate
-20.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Market Perform | $25 → $50 | $20.06 | +149.25% | 8 | Jul 29, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $2.95 | +35.59% | 1 | Jul 8, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $300 → $360 | $467.55 | -23.00% | 5 | Jun 24, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $3.73 | +114.48% | 2 | May 28, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $72 | $44.66 | +61.22% | 1 | Mar 12, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $12.22 | +309.17% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $5.44 | +359.56% | 2 | Mar 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Market Perform | $60 → $45 | $43.24 | +4.08% | 2 | Feb 20, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $50 | $10.13 | +393.83% | 6 | Jan 10, 2025 | |
| DTIL Precision BioSciences | Upgrades: Outperform | $34 | $4.74 | +617.30% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $35 | $17.54 | +99.54% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $1.85 | +818.92% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $6.85 | +483.94% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $35.53 | +153.31% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $20.55 | +483.94% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $16.01 | +256.03% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $50.23 | -26.34% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $58.07 | +72.21% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $3.22 | +490.06% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $52.82 | +85.54% | 1 | Jun 17, 2022 |
Sarepta Therapeutics
Jul 29, 2025
Maintains: Market Perform
Price Target: $25 → $50
Current: $20.06
Upside: +149.25%
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $2.95
Upside: +35.59%
Alnylam Pharmaceuticals
Jun 24, 2025
Maintains: Outperform
Price Target: $300 → $360
Current: $467.55
Upside: -23.00%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $3.73
Upside: +114.48%
Avidity Biosciences
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $44.66
Upside: +61.22%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $12.22
Upside: +309.17%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $5.44
Upside: +359.56%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Market Perform
Price Target: $60 → $45
Current: $43.24
Upside: +4.08%
Intellia Therapeutics
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $10.13
Upside: +393.83%
Precision BioSciences
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $4.74
Upside: +617.30%
Sep 16, 2024
Maintains: Outperform
Price Target: $20 → $35
Current: $17.54
Upside: +99.54%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.85
Upside: +818.92%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $6.85
Upside: +483.94%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $35.53
Upside: +153.31%
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $20.55
Upside: +483.94%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $16.01
Upside: +256.03%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $50.23
Upside: -26.34%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $58.07
Upside: +72.21%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $3.22
Upside: +490.06%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $52.82
Upside: +85.54%